Copertina

Correction to ‘Stromal Vascular Fraction With Platelet‐Rich Plasma Injection During Surgery is Feasible and Safe in Treatment‐Refractory Perianal Fistulising Crohn's Disease: A Pilot Study’

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
di: Jeffrey D McCurdy, et al.
Pubblicazione: (2025)

Editorial: Examining Perianal Fistulising Crohn's Disease Through the Lens of Wound Repair
di: Tim Eglinton
Pubblicazione: (2025)

Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?
di: Jeffrey D McCurdy, et al.
Pubblicazione: (2024)

Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply
di: Runqi Wang, et al.
Pubblicazione: (2026)

Systematic Review of Published Guidelines: Recommendations for Exams Under Anaesthesia, Seton Insertion and Timing of Seton Removal for Perianal and Rectovaginal Fistulising Crohn's Disease
di: Edgard Medawar, et al.
Pubblicazione: (2026)

Editorial: Upadacitinib in Perianal Crohn's Disease
di: Manjeet Kumar Goyal, et al.
Pubblicazione: (2026)

Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real‐Life Retrospective Multicentre Cohort Study
di: Péter Bacsur, et al.
Pubblicazione: (2024)

Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease
di: Runqi Wang, et al.
Pubblicazione: (2026)

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
di: Nicolas Richard, et al.
Pubblicazione: (2026)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises the Importance of Appropriate Patient Selection and Centre Expertise
di: Weilun Gao, et al.
Pubblicazione: (2024)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Reply
di: Péter Bacsur, et al.
Pubblicazione: (2024)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
di: Dingsheng Liu, et al.
Pubblicazione: (2025)

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
di: Emmanuel Pio Pastore
Pubblicazione: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
di: Jeffrey D. McCurdy, et al.
Pubblicazione: (2025)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistula
di: Alyssa M. Parian, et al.
Pubblicazione: (2025)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistulae: Authors' Reply
di: Lichao Qiao, et al.
Pubblicazione: (2025)

Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series
di: Rahul S. Dalal, et al.
Pubblicazione: (2025)

Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease
di: Moeko Komatsu, et al.
Pubblicazione: (2024)

Editorial: “Striding” Towards Transmural Healing: Redefining Deep Remission as a Treatment Target in Crohn's Disease
di: Rohita Reji, et al.
Pubblicazione: (2026)

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
di: Shlomi Cohen, et al.
Pubblicazione: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
di: Tamar Schildkraut, et al.
Pubblicazione: (2024)

Editorial: Upadacitinib—A Promising Induction Agent for Paediatric Crohn's Disease?
di: Vincenzo Stranges, et al.
Pubblicazione: (2025)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
di: Kuan‐Ju Lin, et al.
Pubblicazione: (2025)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Antoine Meyer, et al.
Pubblicazione: (2025)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
di: Matthias Kelm, et al.
Pubblicazione: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
di: Virginia Solitano, et al.
Pubblicazione: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Zhidong Zhou, et al.
Pubblicazione: (2025)

Treatment‐Free Outcomes Following Surgery for IBD : A Nationwide Cohort Study
di: Adam S. Faye, et al.
Pubblicazione: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
di: C. Ramos‐Belinchon, et al.
Pubblicazione: (2025)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
di: Ziheng Calvin Xu, et al.
Pubblicazione: (2025)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
di: Nathan Grellier, et al.
Pubblicazione: (2025)

Editorial: Endoscopic Activity is an Essential Tool for Patients' Management, Even in Mild Crohn's Disease
di: Marco Mendolaro, et al.
Pubblicazione: (2025)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
di: José Luis Rueda García, et al.
Pubblicazione: (2026)

Editorial: Surgery to reduce opioid use in Crohn's disease: Does a classic solution address a newer problem?
di: Tarun Chhibba
Pubblicazione: (2024)

Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006–2021
di: Mehdi Osooli, et al.
Pubblicazione: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease? Authors' Reply
di: Nicolas Richard, et al.
Pubblicazione: (2025)

Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease
di: Mohammad Shehab, et al.
Pubblicazione: (2025)

Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
di: Lingna Ye, et al.
Pubblicazione: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease
di: Jiacheng Li
Pubblicazione: (2026)

Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
di: Maryam Irshad, et al.
Pubblicazione: (2025)